Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
9.42B
Market cap9.42B
Price-Earnings ratio
-10.93
Price-Earnings ratio-10.93
Dividend yield
Dividend yield
Average volume
5.45M
Average volume5.45M
High today
$76.64
High today$76.64
Low today
$74.40
Low today$74.40
Open price
$74.69
Open price$74.69
Volume
698.25K
Volume698.25K
52 Week high
$80.20
52 Week high$80.20
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

With a market cap of 9.42B, Cytokinetics(CYTK) trades at $75.72. The stock has a price-to-earnings ratio of -10.93.

During the trading session on 2026-05-13, Cytokinetics(CYTK) shares reached a daily high of $76.64 and a low of $74.40. At a current price of $75.72, the stock is +1.8% higher than the low and still -1.2% under the high.

Trading volume for Cytokinetics(CYTK) stock has reached 698.25K, versus its average volume of 5.45M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $80.20 and a low of $29.31.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $80.20 and a low of $29.31.

CYTK News

Simply Wall St 1d
Why Cytokinetics Is Up 12.9% After Strong Phase 3 MYQORZO HCM Data And Expanded Reach

Cytokinetics recently reported positive Phase 3 data for MYQORZO (aficamten) in both obstructive and non-obstructive hypertrophic cardiomyopathy, alongside new...

Why Cytokinetics Is Up 12.9% After Strong Phase 3 MYQORZO HCM Data And Expanded Reach
TipRanks 2d
Cytokinetics price target raised to $140 from $136 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cytokinetics (CYTK) to $140 from $136 and keeps a Buy rating on the shares post the Q1 report. The company is...

TipRanks 5d
Cytokinetics Raises $760 Million in Stock Offering

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

More CYTK News

Simply Wall St 6d
Earnings Update: Cytokinetics, Incorporated Just Reported And Analysts Are Boosting Their Estimates

The investors in Cytokinetics, Incorporated's ( ) will be rubbing their hands together with glee today, after the share price leapt 26% to US$74.84 in the week...

Earnings Update: Cytokinetics, Incorporated Just Reported And Analysts Are Boosting Their Estimates

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.